Android app on Google Play

Pluristem (PSTI) Receives Approval to Commence PLX-PAD Phase II in Germany

January 15, 2013 9:22 AM EST Send to a Friend
Get Alerts PSTI Hot Sheet
Trade PSTI Now!
Join SI Premium – FREE
Pluristem Therapeutics, Inc. (Nasdaq: PSTI) announced that the Paul-Ehrlich-Institute (PEI), the medical regulatory body for biological medicinal products for the Federal Republic of Germany, has approved the company's request to initiate a Phase II study using PLX-PAD cells in patients suffering from Intermittent Claudication (IC). IC is a subset of Peripheral Artery Disease (PAD). According to The SAGE Group and HCUP 2007 Inpatient Data, the prevalence of IC in the United States is approximately 14 million patients, representing a cost of approximately $2.5 billion annually to the healthcare system.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment